Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) EBT Margin (2022 - 2025)

Historic EBT Margin for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Q3 2025 value amounting to 7.55%.

  • Arcutis Biotherapeutics' EBT Margin rose 1003600.0% to 7.55% in Q3 2025 from the same period last year, while for Sep 2025 it was 13.62%, marking a year-over-year increase of 1271000.0%. This contributed to the annual value of 70.92% for FY2024, which is 3636400.0% up from last year.
  • Latest data reveals that Arcutis Biotherapeutics reported EBT Margin of 7.55% as of Q3 2025, which was up 1003600.0% from 19.07% recorded in Q2 2025.
  • Arcutis Biotherapeutics' EBT Margin's 5-year high stood at 7.55% during Q3 2025, with a 5-year trough of 14856.41% in Q3 2022.
  • Over the past 4 years, Arcutis Biotherapeutics' median EBT Margin value was 139.14% (recorded in 2023), while the average stood at 1735.59%.
  • In the last 5 years, Arcutis Biotherapeutics' EBT Margin surged by 147172700bps in 2023 and then surged by 330900bps in 2025.
  • Quarter analysis of 4 years shows Arcutis Biotherapeutics' EBT Margin stood at 2432.25% in 2022, then soared by 80bps to 489.86% in 2023, then soared by 97bps to 14.67% in 2024, then soared by 151bps to 7.55% in 2025.
  • Its EBT Margin stands at 7.55% for Q3 2025, versus 19.07% for Q2 2025 and 37.63% for Q1 2025.